![]() | ![]() |
Formats:
|
||||||||||||||||||||||||||||||||||||||||||
NOVEL mRNA ISOFORMS OF THE SODIUM CHANNELS Nav1.2, Nav1.3 AND Nav1.7 ENCODE PREDICTED TWO-DOMAIN, TRUNCATED PROTEINS Departments of Physiology and Pharmacology, and Clinical Sciences South Bristol, School of Medical Sciences, University of Bristol, Bristol, BS8 1TD, UK *Corresponding author. Tel: +44-0-117-3311417; fax: +44-0-117-3312288. D.Wynick/at/bristol.ac.uk (D. Wynick). The publisher's final edited version of this article is available at Neuroscience.Abstract The expression of voltage-gated sodium channels is regulated at multiple levels, and in this study we addressed the potential for alternative splicing of the Nav1.2, Nav1.3, Nav1.6 and Nav1.7 mRNAs. We isolated novel mRNA isoforms of Nav1.2 and Nav1.3 from adult mouse and rat dorsal root ganglia (DRG), Nav1.3 and Nav1.7 from adult mouse brain, and Nav1.7 from neonatal rat brain. These alternatively spliced isoforms introduce an additional exon (Nav1.2 exon 17A and topologically equivalent Nav1.7 exon 16A) or exon pair (Nav1.3 exons 17A and 17B) that contain an in-frame stop codon and result in predicted two-domain, truncated proteins. The mouse and rat orthologous exon sequences are highly conserved (94-100% identities), as are the paralogous Nav1.2 and Nav1.3 exons (93% identity in mouse) to which the Nav1.7 exon has only 60% identity. Previously, Nav1.3 mRNA has been shown to be upregulated in rat DRG following peripheral nerve injury, unlike the downregulation of all other sodium channel transcripts. Here we show that the expression of Nav1.3 mRNA containing exons 17A and 17B is unchanged in mouse following peripheral nerve injury (axotomy), whereas total Nav1.3 mRNA expression is upregulated by 33% (P=0.003), suggesting differential regulation of the alternatively spliced transcripts. The alternatively spliced rodent exon sequences are highly conserved in both the human and chicken genomes, with 77-89% and 72-76% identities to mouse, respectively. The widespread conservation of these sequences strongly suggests an additional level of regulation in the expression of these channels, that is also tissue-specific. Keywords: DRG, brain, alternative splicing, Scn2a, Scn3a, Scn9a Voltage-gated sodium channels mediate the rapid influx of sodium ions that initiate action potentials in excitable cells. The nine mammalian pore-forming α-subunits Nav1.1-Nav1.9 each contain four internally homologous domains (I-IV) that are connected by the three interdomain cytoplasmic loops IDI/II, IDII/III and the smaller IDIII/IV (Plummer and Meisler, 1999; Goldin et al., 2000). Among these channels, the Nav1.5/1.8/1.9 subfamily is resistant to the neurotoxin tetrodotoxin (TTX), whereas the other sodium channels are blocked by nanomolar concentrations and are considered to be TTX-sensitive (Plummer and Meisler, 1999). The expression of mammalian voltage-gated sodium channels can be regulated at multiple levels, including transcription from multiple promoters (Drews et al., 2005; Shang and Dudley, 2005; Martin et al., 2007), alternative splicing of pre-mRNA and different levels of post-translational glycosylation (Diss et al., 2004). One of the best characterized examples of alternative splicing is that of Nav1.2 and Nav1.3 mRNAs which involves the inclusion of either an upstream exon 5N or downstream exon 5A, which encode part of domain I and differ by one or two residues in the 30 encoded amino acids (Sarao et al., 1991; Gustafson et al., 1993; Raymond et al., 2004). In the case of Nav1.2, biophysical differences between the 5N and 5A isoforms have been demonstrated by heterologous expression in HEK293 cells (Xu et al., 2007). Nav1.2 and Nav1.3 transcripts containing exon 5N are predominant in fetal and neonatal brain, whereas in adult brain the exon 5A transcript is predominant (Sarao et al., 1991; Gustafson et al., 1993). Similar brain expression patterns have also been described for Nav1.6 in the adult ((Plummer et al., 1998; Raymond et al., 2004); coding exon 5) and for Nav1.7 in the fetus (Raymond et al., 2004). Interestingly, there is also alternative splicing of exons that encode the corresponding transmembrane segments of Nav1.6 domain III, but in this case the alternative downstream exon 18A encodes 41 amino acids whereas the upstream exon 18N contains an in-frame stop codon that results in the 18N isoform encoding a predicted two-domain protein i.e. a truncated protein that lack domains III and IV (Plummer et al., 1997). Such a truncated protein would not function as a sodium channel (Cox et al., 2006). Nav1.6 mRNA containing exon 18N is the major isoform in fetal brain and is downregulated postnatally, whereas the 18A isoform is expressed in fetal brain and becomes predominant postnatally (Plummer et al., 1997). We have previously characterized alternatively spliced mRNA isoforms encoding the IDII/III cytoplasmic loop of Nav1.8 in adult dorsal root ganglia (DRG) (Kerr et al., 2004) and of the more widely expressed Nav1.5 in adult DRG, brain and heart (Kerr et al., 2004, 2007). In contrast, no alternative splicing of Nav1.9 mRNA was detected in DRG (Kerr et al., 2004). Here, we extend these studies to the TTX-sensitive channels and describe the isolation of novel, conserved mRNA isoforms of Nav1.2, Nav1.3 and Nav1.7 expressed in DRG or brain. Part of the mouse data has been presented previously in abstract form (#622.8, Society for Neuroscience meeting, 2005; http://www.sfn.org). EXPERIMENTAL PROCEDURES Animals, tissue collection, RNA extraction and reverse transcription (RT) All animals were fed standard chow and water ad libitum, and all procedures were carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines. All reasonable efforts were made to minimize animal suffering and to use the minimum number of animals necessary to perform statistically valid analyses. Tissues from 11 week-old male C57BL/6J mice (Bristol University colony, Bristol, UK) and from neonatal (postnatal day 1) or adult male (~300 g) Wistar rats (Bristol University colony) were frozen on dry ice and stored at -80 °C. Total RNA isolation, DNase treatment and re-extraction, and RT reactions with random hexamers were as previously published (Kerr et al., 2004). Studies on peripheral nerve transection (axotomy) were exactly as previously published (Kerr et al., 2004, 2007), with the right sciatic nerve of 10-12 week-old male mice (Bristol University colony) transected at the mid-thigh level, prior to killing 7 days later by cervical dislocation to obtain ipsilateral (axotomized) and contralateral (control) lumbar L4 and L5 DRG pools each from nine animals. Cloning of Nav1.2, Nav1.3, Nav1.6 and Nav1.7 partial-length cDNAs Partial-length cDNAs were each amplified by RT-PCR of 5 μl RT reaction (100 ng of total RNA equivalent) with HPLC-purified primers (Invitrogen, Paisley, Strathclyde, UK; sequences detailed below) for 40 cycles, using previously described PCR conditions (Kerr et al., 2007) except for annealing at 66 °C. Products were excised from ethidium bromide-stained agarose gels (imaged in inverted contrast), purified and TA-cloned into pCRII-TOPO (Invitrogen), all as in Kerr et al. (2007). DNA sequencing was performed by the Department of Biochemistry, Oxford University, now Geneservice. Mouse Nav1.2 forward (5′-GATACGTGAATTCATTCAGAAAGCC-3′) and reverse (5′-GGTTTTCCTCAAGTTCCACCAGAG-3′) primers correspond, respectively, to nucleotides (nt) 159-183 of a mouse anonymous partial-length expressed sequence tag (CF723518) and nt 10,384-10,361 of an anonymous genomic DNA clone (BX284648), each identified using the rat cDNA sequence (NM_012647) (Noda et al., 1986). The expected product spans exons corresponding to human SCN2A exons 17-19 (Kasai et al., 2001). All sequenced clones contained an A residue consistent with nt 8315 of BX284648 (and recent genomic-derived XM_001001618), rather than the corresponding C residue at nt 567 of CF723518. Mouse Nav1.3 forward (5′-TACGGGAGTGCTTCCGAAAAGCG-3′) and reverse (5′-AGGTCTTCCTAAGATTCCACCAGAT-3′) primers correspond, respectively, to nt 137,831-137,809 and nt 125,694-125,718 of an anonymous genomic DNA clone (AL928621), with the expected product spanning exons corresponding to human SCN3A exons 17-19 (Kasai et al., 2001). Mouse Nav1.6 forward (5-GGGCCAAAGTGAAGGTGCATGCC-3′) and reverse (5′-GCCTAGTCCTTCCTCGATGTTGAC-3′) primers correspond, respectively, to nt 3023-3045 and 3537-3514 of the published cDNA sequence (AF049617) (Smith et al., 1998). Spanned sequence corresponds to human SCN8A exons 14-16 (Plummer et al., 1998), topologically equivalent to SCN2A and SCN3A exons 17-19 (Kasai et al., 2001). All sequenced cDNA clones from C57BL/6J (n=24) and 129/OlaHsd (n=10) mouse strains contained the silent nucleotide substitution T3360C, which is also present in an anonymous genomic DNA clone (AC104834, nt 72,387) and recent cDNA sequences (NM_001077499, AK083220). Mouse Nav1.7 forward (5′-TGGCCAGAATTAAAAGAGGGATCAAT-3′) and reverse (5′-GGTCTTCCTGATGGTCCACCAAAC-3′) primers correspond, respectively, to nt 119,164-119,139 and 100,775-100,798 of a mouse anonymous genomic DNA clone (AL928726) identified using the rat cDNA sequence (NM_133289) (Sangameswaran et al., 1997). The expected product spans exons corresponding to human SCN9A exons 16-18 (exon numbering following (Yang et al., 2004; Cox et al., 2006)), equivalent to SCN2A and SCN3A exons 17-19 (Kasai et al., 2001). Rat Nav1.2 primers 5′-AGCCTTTGTCAGAAAGCAGAAAGCTTT-3′ and 5′-CTTATCTGACAACACTTGAACTTTCTC-3′ correspond, respectively, to nt 3291-3317 and 3764-3738 of NM_012647 (Noda et al., 1986). Rat Nav1.3 primers 5′-GAAAAATAAGATACGGGAGTGCTTCCG-3′ and 5′-TTCTTCTGTACTTACTTGACAGAAGG-3′ correspond, respectively, to nt 3320-3346 and 3824-3799 of NM_013119 (Kayano et al., 1988). Rat Nav1.6 primers 5′-GGACCAAAGTGAAGGTGCACGCCT-3′ and 5′-ACTTGCCTAGTCCTTCCTCGATGTTG-3′ correspond, respectively, to nt 3017-3040 and 3535-3510 of L39018 (Schaller et al., 1995) and share identity within NM_019266 (Dietrich et al., 1998). Rat Nav1.7 primers 5′-GGAATCAATTACGTGAAACAGACCCT-3′ and 5′-AACTTTCCCTTTCCCAGAGTCTACAT-3′ correspond, respectively, to nt 2989-3014 and 3525-3500 of NM_133289 (Sangameswaran et al., 1997). Real-time quantitative RT-PCR assays Real-time quantitative RT-PCR assays were used to derive relative mRNA expression levels by the comparative threshold cycle (Ct) method, as previously described along with the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) primer and probe set (Kerr et al., 2007). Primer and probe sets (Applied Biosystems, Warrington, Cheshire, UK) for products of 75-150 base pairs (bp) were designed using Primer Express software (Applied Biosystems), and the probes detailed below had the 5′ fluorescent reporter dye FAM (6-carboxyfluorescein) and the 3′ quencher dye TAMRA (6-carboxy-tetramethyl-rhodamine). Primers and probe to detect the mouse Nav1.3 mRNA isoform that includes exons 17A and 17B were: forward primer 5′-ACCCAG/TATCACAACTCTGGCAAT-3′ (where/denotes the exon 17A/17B junction, see Fig. 2B and C
The specificity of each assay was demonstrated by testing against a panel of cDNA plasmids (Nav1.2; Nav1.2 (exon 17A); Nav1.3; Nav1.3 (exon 17A[83nt]+17B); Nav1.3 (exon17A[92nt]+17B); Nav1.5; Nav1.6; Nav1.7; Nav1.7 (exon 16A); Nav1.8; and Nav1.9), and each assay amplified a single product of the expected size from DRG (data not shown). DRG expression levels were normalized to GAPDH mRNA, which is unchanged following peripheral nerve injury (Macdonald et al., 2001; Kerr et al., 2007), and results are presented as mean±S.E. of log-transformed data. The statistical significance of differences between control and axotomy samples was judged by two-tailed paired t-test, and between different genes after axotomy by two-way ANOVA with a Scheffé multiple comparison. P<0.05 was considered statistically significant. Bioinformatics The publicly available mouse (build 36, May 2006; strain C57BL/6J), rat (build 4, alternative assembly, July 2006; mixture of Brown Norway (BN) and Sprague-Dawley strains), human (build 36) and chicken (build 2.1) genomes were accessed using megaBLAST and cross-species megaBLAST (http://ncbi.nlm.nih.gov/genome/seq/). The SECISearch 2.19 program (http://genome.unl.edu-SECISearch) was used to search for potential selenocysteine insertion sequences (Kryukov et al., 2003). RESULTS Expression of Nav1.2, 1.3, 1.6 and 1.7 mRNAs in mouse DRG and brain In order to study the expression of mouse Nav1.2, 1.3, 1.6 and 1.7 mRNAs, gene-specific primers were designed to amplify across the three expected exons that encode the second (interdomain IDII/III) cytoplasmic loop (Plummer et al., 1998; Kasai et al., 2001). The interdomain cytoplasmic loops IDI/II and IDII/III are the least conserved regions between the different voltage-gated sodium channels (Schaller et al., 1995; Chen et al., 1997), and we have previously described alternatively spliced mRNA isoforms of Nav1.5 and Nav1.8 encoding the IDII/III cytoplasmic loop (Kerr et al., 2004, 2007). In addition to Nav1.2, 1.3, 1.6 and 1.7 RT-PCR products of the expected size (Fig. 1A
To address the possibility of tissue-specific expression of these novel mRNA isoforms, expression of each channel was also studied in adult mouse brain. In addition to major RT-PCR products of the expected size (Fig. 1B and C Expression of Nav1.3 mRNA isoforms in mouse DRG after axotomy Following peripheral nerve injury, Nav1.3 mRNA levels have been reported to be upregulated ~twofold in rat DRG (Kim et al., 2001; Hains et al., 2004) whereas the other voltage-gated sodium channel transcripts are downregulated by ~40-80% (Kim et al., 2001, 2002; Raymond et al., 2004). To assess the effect of peripheral nerve transection (axotomy) on the expression of mouse Nav1.3 mRNA isoforms, real-time quantitative RT-PCR assays were optimized for Nav1.3 mRNA containing exons 17A and 17B (hereafter 17A+B), and for ‘total’ Nav1.3 mRNA (i.e. detecting the isoforms both including and excluding exons 17A+B). Note that the presence of the Nav1.3-specific exon 17B allowed the design of the specific assay to Nav1.3 mRNA containing exons 17A+B that did not cross-react with other sodium channels (see Experimental Procedures). Specific assays for Nav1.3 mRNA excluding exons 17A+B or for Nav1.2 mRNA containing exon 17A could not be designed due to the high sequence similarity of the relevant region of the Nav1.1/Nav1.2/Nav1.3 upstream exons (respective Nav1.2/1.3, Nav1.2/1.1 and Nav1.3/1.1 nucleotide identities in the 3 window of 75 nt are 89.3%, 90.7% and 89.3%) and the high level of sequence conservation (93%) between exons 17A of Nav1.2 (Scn2a) and Nav1.3 (Scn3a). Control real-time RT-PCR assays were also optimized for Nav1.6 and galanin, which have previously been shown to be, respectively, downregulated and upregulated in rat DRG after peripheral nerve injury (Macdonald et al., 2001; Kim et al., 2002; Raymond et al., 2004). Seven days after axotomy, the expression of Nav1.3 mRNA containing exons 17A+B was unchanged from control (P>0.05), whereas total Nav1.3 mRNA increased by 33% compared with control (P=0.003) in mouse lumbar L4 and L5 DRG (Fig. 4
Expression of Nav1.2, 1.3, 1.6 and 1.7 mRNAs in rat DRG and brain If the novel exons expressed in the mouse are biologically important, they would be expected to be conserved between species. As in the mouse, adult rat DRG expressed Nav1.2, Nav1.3, Nav1.6 and Nav1.7 mRNAs with RT-PCR products of the expected size and sequence (each n=12) along with novel, larger isoforms of Nav1.2 and Nav1.3 (Fig. 5A and B
Adult rat brain expressed Nav1.2, Nav1.3, Nav1.6 and Nav1.7 mRNAs, but no larger Nav1.3 or Nav1.7 mRNA isoforms equivalent to those found in mouse brain were detected (Fig. 5C The splice sites sequences of the alternatively spliced mouse and rat exons As shown in Table 1, the novel Scn2a (Nav1.2), Scn3a (Nav1.3) and Scn9a (Nav1.7) exons are each flanked by introns with the canonical GT and AG dinucleotides at the 5′ and 3′ splice sites, respectively, except for the mouse Scn3a exon 17A variant of 92 nt and rat SCN2A exon 17A variant of 93 nt that result from selecting a downstream donor splice site of a GC-AG intron (see Discussion). By comparison to the consensus mammalian 5′ splice site sequence (C/A)AG/GT(A/G)AGT (exon nt in bold; (Burset et al., 2001)), the conserved CAG/GTTACC of mouse/rat Scn2a and Scn3a introns 17A and the corresponding Scn9a intron 16A each differ at the underlined positions +3, +5 and +6 (respective mammalian nucleotide frequencies: T=2.5%; C=5.5% and C=16.5%; (Burset et al., 2001)). In addition, they do not conform to the strong tendency for a thymine (T) residue at position +3 to occur along with a guanine (G) at position +5 (Clark and Thanaraj, 2002), though cytosine (C) residues at positions +5 and +6 are known to be more common in alternative cassette exons expressed in neurons (Stamm et al., 2000).
The rodent novel exon sequences are highly conserved in the human and chicken genomes Human genomic sequences with high nucleotide sequence identity to the novel exons identified in mouse and rat were identified in silico in the corresponding locations of SCN2A (87% identity), SCN3A (exons 17A and 17B: respectively 85% and 89% identities) and SCN9A (77% identity) (Fig. 6A-D
A useful outgroup to the mammals is provided by the chicken (Gallus gallus) genome sequence, in which three putative alternative exons were also identified (Fig. 6 DISCUSSION Nav1.2, Nav1.3, Nav1.6 and Nav1.7 mRNAs were each detected in DRG and brain from adult mouse and rat (Figs. (Figs.11 The alternatively spliced mRNA isoforms of Nav1.2 and Nav1.3 were expressed in both adult mouse and rat DRG, and alternatively spliced mRNA isoforms of Nav1.3 and Nav1.7 were expressed in adult mouse brain (Figs. (Figs.11 There has been much interest in Nav1.3 expression following the finding that Nav1.3 mRNA is the only sodium channel transcript that is upregulated in the rat DRG after nerve injury (Waxman et al., 1994; Dib-Hajj et al., 1996; Kim et al., 2001, 2002; Raymond et al., 2004; Hains et al., 2004). Specifically, Nav1.3 mRNA was shown to increase after axotomy, as detected by in situ hybridization and semi-quantitative RT-PCR (Waxman et al., 1994; Dib-Hajj et al., 1996); to increase by ~twofold between 3 and 7 days after spinal nerve ligation (SNL; Chung model), as determined by RNase protection assay (Kim et al., 2001); and to increase 1.8-fold 10 days after chronic constriction injury (CCI), as determined by quantitative RT-PCR (Hains et al., 2004). Here we report that following peripheral axotomy in the mouse, there was a smaller but still significant increase of 33% in total Nav1.3 mRNA (i.e. isoforms both including and excluding exons 17A+B) whereas expression of the alternatively spliced Nav1.3 mRNA containing exons 17A+B did not change significantly (Fig. 4 The exon 17A sequences of mouse/rat Nav1.2 and rat Nav1.3 mRNAs each include an in-frame TGA termination codon (Fig. 2 A predicted two-domain protein is also encoded by the Nav1.6 mRNA isoform containing exon 18N (see introduction), which was proposed as a ‘fail-safe’ mechanism to prevent the synthesis or activity of full-length protein (Plummer et al., 1997). The mammalian Nav1.6 (Scn8a) exon 18N and 18A sequences are conserved in the homologous gene of pufferfish (Fugu rubripes)(Plummer et al., 1997), and in both the voltage-gated sodium channel genes scn8ab of zebrafish (Danio rerio) and BgNav (formerly paraCSMA) of German cockroach (Blattella germanica) there is regulated alternative splicing at this site resulting in mRNA isoforms with a PTC that encode predicted two-domain proteins, strongly suggesting a conserved biological function (Tan et al., 2002; Novak et al., 2006b). Among mammalian voltage-gated calcium channel α1 subunits, which are members of the same super-family and that usually have the same four-domain structure, a predicted two-domain Cav2.2 protein results from the introduction of a cassette exon with a PTC that is conserved in human, rat and mouse (Raghib et al., 2001). Also, a predicted two-domain Cav1.2 results from the introduction of a 12 nt segment containing a PTC (Soldatov, 1994; Ertel et al., 2000; Tang et al., 2004) and a 95 kDa, two-domain isoform of Cav2.1 has been purified that can still interact with its auxiliary β subunit (Scott et al., 1998; Ertel et al., 2000). Heterologously expressed two-domain channels did not produce detectable inward Ca2+ currents (i.e. no evidence of homodimerization to form a functional channel), although subcellular localization was similar to four-domain channels (Raghib et al., 2001; Ahern et al., 2001), and co-expression of two-domain and four-domain calcium channels resulted in a dominant-negative suppression of Ca2+ currents that may be due to the sequestration of interacting proteins (Raghib et al., 2001; Jeng et al., 2006; Raike et al., 2007). Human putative exon sequences were identified that have high sequence similarity to the alternatively spliced mouse/rat Scn2a and Scn3a exons 17A (85-89% identities; Fig. 6 The comparison of mammalian and phylogenetically distant chicken sequences has been used recently to address the evolutionary conservation of alternatively spliced products (Katyal et al., 2007; Tang et al., 2007). Here, sequences with 72-76% nucleotide identity to the mouse alternatively spliced exons were identified within the chicken SCN2A/locus395945, SCN3A/locus424180 and SCN9A genes (Fig. 6 The identification of these alternatively spliced exon sequences, which are widely conserved, could be of relevance in human disease states. It is known that mutations can affect splice sites of sodium channels (Moric et al., 2003; Mulley et al., 2005; Rossenbacker et al., 2005; Goldberg et al., 2007; Harkin et al., 2007) and that an intronic polymorphism can alter the ratios of alternatively spliced transcripts containing either exons 5N or 5A (Heinzen et al., 2007). The misregulated alternative splicing of SCN9A (Nav1.7) exon 16A or of SCN2A and SCN3A exons 17A could result in either an upregulation of non-functional, predicted two-domain proteins with a concomitant downregulation of functional, four-domain channels, or vice versa. Gain-of-function mutations of SCN9A cause primary erythermalgia (Yang et al., 2004; Cummins et al., 2004) and paroxysmal extreme pain disorder (Fertleman et al., 2006), whereas loss-of-function mutations are associated with the inability to sense pain (Cox et al., 2006; Goldberg et al., 2007), and SCN2A mutations have been detected in patients with epilepsy (Striano et al., 2006; Scalmani et al., 2006; Herlenius et al., 2007) and in a case of autism (Weiss et al., 2003). Therefore, screening of these putative exons and their flanking sequences for mutations could be informative in various human diseases associated with these channels. It is also possible that species-specific control of SCN9A (Nav1.7) alternative splicing could help account for the difference in phenotype between the human loss of pain sensation due to loss-of-function mutations (Cox et al., 2006; Goldberg et al., 2007) and the perinatal lethality of Scn9a-/- knockout mice (Nassar et al., 2004). CONCLUSION In summary, we describe the isolation of alternatively spliced mRNA isoforms of mouse and rat Nav1.2, Nav1.3 and Nav1.7, each with novel exons that include an in-frame stop codon and therefore encode predicted two-domain, truncated proteins. Currently, it is not known whether the expression of these alternatively spliced mRNAs acts as a ‘fail-safe’ mechanism to prevent four-domain channel synthesis via making a substrate for nonsense-mediated mRNA decay, or is for the synthesis of two-domain proteins that may still interact with ankyrin-G. Whichever proves to be the case, we propose that the widespread conservation of these sequences (rodents/human/bird) strongly suggests an additional level of regulation in these voltage-gated sodium channels. Acknowledgments We thank Dr. Linda Hunt (Institute of Child Health, University of Bristol) for advice on statistics and Robert Pope (Dept. of Physiology and Pharmacology, University of Bristol) for help with figures. Nucleotide sequence data reported are available in the DDBJ/EMBL/GenBank databases under the accession numbers AM905319-AM905326. Abbreviations
REFERENCES
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||||||||||||||||||||||||||
Genomics. 1999 Apr 15; 57(2):323-31.
[Genomics. 1999]Neuron. 2000 Nov; 28(2):365-8.
[Neuron. 2000]Genomics. 2005 Feb; 85(2):245-57.
[Genomics. 2005]J Biol Chem. 2005 Jan 14; 280(2):933-40.
[J Biol Chem. 2005]Genomics. 2007 Aug; 90(2):225-35.
[Genomics. 2007]Eur Biophys J. 2004 May; 33(3):180-93.
[Eur Biophys J. 2004]Nucleic Acids Res. 1991 Oct 25; 19(20):5673-9.
[Nucleic Acids Res. 1991]J Biol Chem. 2004 Jun 4; 279(23):24826-33.
[J Biol Chem. 2004]Mol Cell Neurosci. 2007 Jun; 35(2):283-91.
[Mol Cell Neurosci. 2007]J Biol Chem. 2004 Jun 4; 279(23):24826-33.
[J Biol Chem. 2004]J Biol Chem. 2004 Jun 4; 279(23):24826-33.
[J Biol Chem. 2004]Mol Cell Neurosci. 2007 Jun; 35(2):283-91.
[Mol Cell Neurosci. 2007]Mol Cell Neurosci. 2007 Jun; 35(2):283-91.
[Mol Cell Neurosci. 2007]Nature. 1986 Mar 13-19; 320(6058):188-92.
[Nature. 1986]Gene. 2001 Feb 7; 264(1):113-22.
[Gene. 2001]Gene. 2001 Feb 7; 264(1):113-22.
[Gene. 2001]J Neurosci. 1998 Aug 15; 18(16):6093-102.
[J Neurosci. 1998]Genomics. 1998 Dec 1; 54(2):287-96.
[Genomics. 1998]Gene. 2001 Feb 7; 264(1):113-22.
[Gene. 2001]J Biol Chem. 1997 Jun 6; 272(23):14805-9.
[J Biol Chem. 1997]J Med Genet. 2004 Mar; 41(3):171-4.
[J Med Genet. 2004]Nature. 2006 Dec 14; 444(7121):894-8.
[Nature. 2006]Gene. 2001 Feb 7; 264(1):113-22.
[Gene. 2001]Nature. 1986 Mar 13-19; 320(6058):188-92.
[Nature. 1986]FEBS Lett. 1988 Feb 8; 228(1):187-94.
[FEBS Lett. 1988]J Neurosci. 1995 May; 15(5 Pt 1):3231-42.
[J Neurosci. 1995]J Neurochem. 1998 Jun; 70(6):2262-72.
[J Neurochem. 1998]J Biol Chem. 1997 Jun 6; 272(23):14805-9.
[J Biol Chem. 1997]Mol Cell Neurosci. 2007 Jun; 35(2):283-91.
[Mol Cell Neurosci. 2007]Genomics. 1998 Dec 1; 54(2):287-96.
[Genomics. 1998]J Neurosci. 1998 Aug 15; 18(16):6093-102.
[J Neurosci. 1998]Brain Res Mol Brain Res. 2001 May 20; 90(1):48-56.
[Brain Res Mol Brain Res. 2001]Mol Cell Neurosci. 2007 Jun; 35(2):283-91.
[Mol Cell Neurosci. 2007]Science. 2003 May 30; 300(5624):1439-43.
[Science. 2003]Genomics. 1998 Dec 1; 54(2):287-96.
[Genomics. 1998]Gene. 2001 Feb 7; 264(1):113-22.
[Gene. 2001]J Neurosci. 1995 May; 15(5 Pt 1):3231-42.
[J Neurosci. 1995]Gene. 1997 Nov 20; 202(1-2):7-14.
[Gene. 1997]J Biol Chem. 2004 Jun 4; 279(23):24826-33.
[J Biol Chem. 2004]Gene. 2001 Feb 7; 264(1):113-22.
[Gene. 2001]J Med Genet. 2004 Mar; 41(3):171-4.
[J Med Genet. 2004]Nature. 2006 Dec 14; 444(7121):894-8.
[Nature. 2006]Gene. 2001 Feb 7; 264(1):113-22.
[Gene. 2001]Brain Res Mol Brain Res. 2001 Nov 1; 95(1-2):153-61.
[Brain Res Mol Brain Res. 2001]J Neurosci. 2004 May 19; 24(20):4832-9.
[J Neurosci. 2004]Neurosci Lett. 2002 Apr 26; 323(2):125-8.
[Neurosci Lett. 2002]J Biol Chem. 2004 Oct 29; 279(44):46234-41.
[J Biol Chem. 2004]Brain Res Mol Brain Res. 2001 May 20; 90(1):48-56.
[Brain Res Mol Brain Res. 2001]Mol Cell Neurosci. 2007 Jun; 35(2):283-91.
[Mol Cell Neurosci. 2007]Brain Res Mol Brain Res. 2001 May 20; 90(1):48-56.
[Brain Res Mol Brain Res. 2001]Nucleic Acids Res. 2001 Jan 1; 29(1):255-9.
[Nucleic Acids Res. 2001]Hum Mol Genet. 2002 Feb 15; 11(4):451-64.
[Hum Mol Genet. 2002]DNA Cell Biol. 2000 Dec; 19(12):739-56.
[DNA Cell Biol. 2000]J Neurosci. 1995 May; 15(5 Pt 1):3231-42.
[J Neurosci. 1995]Brain Res Mol Brain Res. 1997 Apr; 45(1):71-82.
[Brain Res Mol Brain Res. 1997]J Biol Chem. 1997 Jun 6; 272(23):14805-9.
[J Biol Chem. 1997]J Neurochem. 1998 Jun; 70(6):2262-72.
[J Neurochem. 1998]Brain Res Mol Brain Res. 2001 Nov 1; 95(1-2):153-61.
[Brain Res Mol Brain Res. 2001]J Physiol. 2005 May 1; 564(Pt 3):683-96.
[J Physiol. 2005]J Physiol. 2005 Jan 1; 562(Pt 1):223-34.
[J Physiol. 2005]Mol Cell Biol. 1999 May; 19(5):3225-36.
[Mol Cell Biol. 1999]Nucleic Acids Res. 2000 Nov 1; 28(21):4364-75.
[Nucleic Acids Res. 2000]Gene. 2001 Feb 7; 264(1):113-22.
[Gene. 2001]J Neurophysiol. 1994 Jul; 72(1):466-70.
[J Neurophysiol. 1994]Proc Natl Acad Sci U S A. 1996 Dec 10; 93(25):14950-4.
[Proc Natl Acad Sci U S A. 1996]Brain Res Mol Brain Res. 2001 Nov 1; 95(1-2):153-61.
[Brain Res Mol Brain Res. 2001]Neurosci Lett. 2002 Apr 26; 323(2):125-8.
[Neurosci Lett. 2002]J Biol Chem. 2004 Oct 29; 279(44):46234-41.
[J Biol Chem. 2004]Genomics. 2006 Dec; 88(6):690-7.
[Genomics. 2006]Science. 2003 May 30; 300(5624):1439-43.
[Science. 2003]Nat Rev Mol Cell Biol. 2006 Jun; 7(6):415-25.
[Nat Rev Mol Cell Biol. 2006]Proc Natl Acad Sci U S A. 2003 Jan 7; 100(1):189-92.
[Proc Natl Acad Sci U S A. 2003]Genome Biol. 2004; 5(4):218.
[Genome Biol. 2004]J Biol Chem. 1997 Sep 19; 272(38):24008-15.
[J Biol Chem. 1997]J Neurosci. 2002 Jul 1; 22(13):5300-9.
[J Neurosci. 2002]Dev Dyn. 2006 Jul; 235(7):1962-73.
[Dev Dyn. 2006]J Neurosci. 2001 Nov 1; 21(21):8495-504.
[J Neurosci. 2001]Genomics. 1994 Jul 1; 22(1):77-87.
[Genomics. 1994]Nat Genet. 2003 Jun; 34(2):177-80.
[Nat Genet. 2003]Genome Biol. 2006; 7(1):R5.
[Genome Biol. 2006]BMC Mol Biol. 2007 May 23; 8():42.
[BMC Mol Biol. 2007]Genome Res. 2003 Jul; 13(7):1631-7.
[Genome Res. 2003]Genome Res. 2004 Aug; 14(8):1617-23.
[Genome Res. 2004]Cytogenet Genome Res. 2007; 117(1-4):146-57.
[Cytogenet Genome Res. 2007]Cytogenet Genome Res. 2007; 117(1-4):268-77.
[Cytogenet Genome Res. 2007]Genomics. 2007 Aug; 90(2):225-35.
[Genomics. 2007]Neuron. 2000 Nov; 28(2):365-8.
[Neuron. 2000]Nature. 2004 Dec 9; 432(7018):695-716.
[Nature. 2004]Europace. 2003 Oct; 5(4):325-34.
[Europace. 2003]Hum Mutat. 2005 Jun; 25(6):535-42.
[Hum Mutat. 2005]J Med Genet. 2005 May; 42(5):e29.
[J Med Genet. 2005]Clin Genet. 2007 Apr; 71(4):311-9.
[Clin Genet. 2007]Brain. 2007 Mar; 130(Pt 3):843-52.
[Brain. 2007]Gene. 2001 Feb 7; 264(1):113-22.
[Gene. 2001]J Med Genet. 2004 Mar; 41(3):171-4.
[J Med Genet. 2004]Nature. 2006 Dec 14; 444(7121):894-8.
[Nature. 2006]Epilepsia. 2006 Jan; 47(1):218-20.
[Epilepsia. 2006]Genomics. 2007 Aug; 90(2):225-35.
[Genomics. 2007]